Navigation Links
Predicting acute GVHD by gene expression could improve liver stem cell transplant outcomes
Date:7/20/2008

Tampa, Fla. (July 21, 2008) Many cell transplants involve the use of stem cells from another human being (known as an allograft), which raises the major concern of the potential for acute graft-versus-host disease (GVHD). GVHD occurs when an immune response is elicited by the grafted cells against the recipient, resulting in tissue damage for the treated individual.

Presently, there are no definitive markers for predicting the development of acute graft-versus-host disease (GVHD) or its progression following the transplant of allogenic stem cells as therapy for liver cancer.

However, in a study published in the current issue CELL TRANSPLANTATON (17:5), researchers at the University of Florida offer a preliminary "molecular signature" based on gene expression for the development of acute GVHD following allogenic hematopoietic stem cell transplants (HSCT).

Despite immunosuppressive drugs, acute GVHD can develop within 100 days post-transplant. Where tissue damage in the skin, liver and gastrointestinal tract is extensive, prognosis can be poor. Although clinicians can identify a well-defined pathophysiological mechanism for acute graft-versus-host disease (GVHD), being able to uncover molecular markers for a patient's potential to develop GVHD would be a significant breakthrough.

"Our study enrolled four acute GVHD patients and four acute GVHD-free patients and noted significant differences in the expression of 1,658 genes between the control and acute GVHD patients," explained Vijay Reddy, MD, PhD, the study's lead author.

Of the 1,658 genes observed, immune-related genes showed the greatest amount of change.

"We observed a predominately pro-inflammatory gene expression profile in acute GVHD patients, consistent with our knowledge of how GVHD develops," concluded Reddy. "Perhaps the most valuable finding was having discovered the possible role for IL-27, IL-22 and Th17 cellular inflammatory responses in the development of a
'/>"/>

Contact: Vijay Reddy, MD, PhD
vijay.reddy.md@flhosp.org
352-846-1749
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Page: 1 2

Related biology news :

1. Trial seeks genetic fingerprint for predicting drug effectiveness
2. Predicting growth hormone treatment success
3. Predicting the radiation risk to ESAs astronauts
4. Predicting the perfect predator
5. Predicting the distribution of creatures great and small
6. Tolerance to inhalants may be caused by changes in gene expression
7. Unique pattern of gene expression can indicate acetaminophen overdose
8. Powerful integration of lipid metabolic profiling with gene expression analysis
9. Gene-environment interaction in yeast gene expression
10. Scientists discover small RNAs that regulate gene expression and protect the genome
11. Newly created cancer stem cells could aid breast cancer research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... the course of a lifetime, the heart pumps some 25... order to do this, the muscle fibers of the heart ...eaded by Dr. Wolfgang Rottbauer, vice chair of the...ty Hospital (Chairman: Prof. Dr. H. A. Katus), has...stability of the smallest muscular unit, the sarco...
(Date:11/25/2009)... JOLLA, CAWhen you eat may be just as vital to you... Salk Institute for Biological Studies. Their expe... waning of thousands of genes in the liverthe body...food intake and not by the body,s circadian clock ...me determines the activity of a large number of ge...
(Date:11/24/2009)...Lupus Research Institute (LRI) today named 12 new ....6 million, recognize innovative work across a bro...or their creativity, novelty, and potential to dri...at, and cure the complex disease of systemic lupus...ed lupus researchers across the nation and include...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Feeding the clock 2Feeding the clock 3Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 1Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 2Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 3Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 4Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 5Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 6Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 1Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 2Study reveals 2 3 of prostate cancer patients do not need treatment 58130 1Study reveals 2 3 of prostate cancer patients do not need treatment 58130 2
...r the past 60 years, the National Academies have s... Japanese survivors of the atomic bombs dropped on...e Atomic Bomb Casualty Commission (ABCC), the stud...ion Effects Research Foundation (RERF), which is n... To commemorate the many contributions of former ...
...ne talented life scientists will receive the 2007 ...te and set up their research groups in Croatia, th...rkey. These nine scientists are the second group o...ganization (EMBO) introduced the scheme in 2006. ,...d aim to strengthen science in selected member sta...
...ter decoding the genomes of various plants, animal...as the next major step that will drive biological ... spell all the letters in the genetic material, ho...ering this complex code. Pharma- and biotechnology...m new tools for use in drug discovery and developm...
Other Biology News:Atomic bomb survivor, scientists mark 60 years of long-term radiation study 2EMBO Installation Grants help 9 scientists set up in Europe 2World class in Systems Biology is the aim 2World class in Systems Biology is the aim 3World class in Systems Biology is the aim 4
(Date:11/25/2009)... , , DURHAM, N.C., Nov. 25 /PRNewsw...nveiled the first energy-efficient, single-treatme...d from carbon nanotubes to Andhra Pradesh, Ministe...d other leaders in Hyderabad, India today. Initial...y (IIT) Kanpur, confirmed that the majority of the...
(Date:11/25/2009)... , , BEIJING, Nov. 25 /PRNewsw...g developer and provider of vaccines, announced to...t to establish Sinovac (Dalian) Vaccine,Technology... develop, produce,and commercialize human-use vacc...perience in developing and commercializing world-c...
(Date:11/24/2009)... , Ambassador to also Vis...mber 24, 2009 -- , , ,Who: David Appia, French Amb... and CEO of the Invest in France Agency, , , , ,W...ess to discuss recent pro-business initiatives ado...iscal and academic landscape for innovation and de...
(Date:11/24/2009)... , , ST. LOUIS, Nov. 24 /PRNewswire-Fi...AL ) will be presenting at the NASDAQ OMX conferen...on, 7:45 AM US/CST. Interested parties may listen ...le at http://inve s tor.sig m a a ldrich.c...ss this file. ,, About Sigma-Aldrich: Sig...
Breaking Biology Technology:North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3
...D, N.J., Nov. 13 Covanta Holding,Corporation (NYS...n and,ownership of Energy-from-Waste and renewable...ended its agreement to purchase two biomass energy... and Indeck Energy,Services, Inc., Pursuant to th... these,two facilities for approximately $52 millio...
... Can Invest Simultaneously in Future Healthcare an...ternational Inc., one of the world,s largest and m...try leader in stem cell innovation, recently,renew...promise(R) the,largest private source of college f...Cell has been the only cord blood bank in the Unit...
...Calif., Nov. 13 Cardiogenesis,Corporation (Pink S...ucts,used in the treatment of patients suffering f...s for its third quarter ended September 30, 2008.,...hird quarter of 2008 totaled $2,618,000, a 25% dec...3,486,000. The lower revenue in,the current year q...
Other Biology Technology:Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 2Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 3Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 4Cryo-Cell Renews Upromise Industry-Exclusive Agreement 2Cryo-Cell Renews Upromise Industry-Exclusive Agreement 3Cryo-Cell Renews Upromise Industry-Exclusive Agreement 4Cardiogenesis Reports Third Quarter 2008 Results 2Cardiogenesis Reports Third Quarter 2008 Results 3Cardiogenesis Reports Third Quarter 2008 Results 4Cardiogenesis Reports Third Quarter 2008 Results 5Cardiogenesis Reports Third Quarter 2008 Results 6Cardiogenesis Reports Third Quarter 2008 Results 7
FMK Negative Control from BioVision
Amino Acid Mixture, Complete from Promega
...vatives that have mutations in both the thioredoxi... genes, which greatly enhances disulfide bond form...pression in Origami(DE3) yielded 10-fold more acti...l expression levels were similar (1). Origami host...
Caspase-6 Inhibitor Z-VEID-FMK from BioVision
Biology Products: